Abstract: The disclosure provides novel molecules related to growth and differentiation factor-8 (GDF8), in particular epitopes specific to GDF8 and other specific antagonists of GDF8 in particular anti-GDF8 antibodies or antigen binding protein or fragment thereof which may inhibit GDF8 activity and signal in vitro and/or in vivo. The disclosure also provides for an immunoassay used to detect and quantitate GDF8. The disclosure also provides methods for diagnosing, preventing, ameliorating, and treating GDF8-associated disorders, e.g., degenerative orders of muscle, bone, and insulin metabolism. Finally, the disclosure provides pharmaceuticals for the treatment of such disorders by using the antibodies, polypeptides, polynucleotides, and vectors of the invention.

Abstract: Nucleic acids encoding a new family of small cysteine rich soluble proteins, from a mammal, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.

Abstract: An amphiphilic substance includes a hydrophobic group, and a polynucleotide group attached to the hydrophobic group. The polynucleotide group includes a first polynucleotide segment and a second polynucleotide segment. The first and second polynucleotide segments are at least partially complementary and are bound together by interactions including base pairing. At least one of the first and second segments includes at least one of an aptamer and a nucleic acid-based enzyme. A lipid vesicle may include the amphiphilic substance, a first polar lipid that is an unstable vesicle former, and a polar liquid. Upon exposure to a rupture agent, the vesicle may rupture, releasing the contents of the vesicle. Substances that may be released from the vesicle include bioactive agents, such as drug agents.

Abstract: The present invention provides novel peptides of specified sequence and their use as a signal peptide or a membrane-anchoring peptide. It also relates to chimeric polypeptide comprising one or more such peptides and a polypeptide of interest as well as nucleic acid molecules, vectors, infections vital particles and host cells encoding such peptides and chimeric polypeptides. The present invention also relates to a pharmaceutical composition comprising such elements and a pharmaceutically acceptable vehicle. The present invention also provides a method for recumbently producing a polypeptide using such peptides, especially for directing expression of a polypeptide of interest extracellularly or anchored at the surface of the plasma membrane.

Abstract: Nucleic acid comprising or encoding an RNA replica comprising, in this order, the following segments (i) to (iii): i) a nucleic acid sequence encoding a potexvirus RNA-dependent RNA polymerase or a function-conservative variant thereof; ii) a nucleic acid sequence comprising: a) a potexvirus triple gene block or a function-conservative variant thereof and b) a sequence encoding a potexviral coat protein or a function-conservative variant thereof; or a sequence encoding a tobago viral movement protein; and iii) a heterologous nucleic acid sequence expressible from said replica in a plant or in plant tissue.

Abstract: Methods and compositions for staining based upon nucleic acid sequence that employ nucleic acid probes are provided. Said methods produce staining patterns that can be tailored for specific cytogenetic analyzes. Said probes are appropriate for in situ hybridization and stain both interphase and metaphase chromosomal material with reliable signals. The nucleic acid probes are typically of a complexity greater than 50 kb, the complexity depending upon the cytogenetic application. Methods and reagents are provided for the detection of genetic rearrangements. Probes and test kits are provided for use in detecting genetic rearrangements, particularly for use in tumor cytogenetics, in the detection of disease related loci, specifically cancer, such as chronic myelogenous leukemia (CML) and for biological dosimetry. Methods and reagents are described for cytogenetic research, for the differentiation of cytogenetically similar but genetically different diseases, and for many prognostic and diagnostic applications.

Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.

Abstract: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.

Abstract: Nucleic acid material can be effectively separated from a fluid by first contacting the fluid with a positively charged polymer which binds the nucleic acid material. Thereafter, the polymer, having the nucleic acid material bonded thereto, is contacted with a releasing agent which comprises a solution of an alkaline material and a glycol. The solution has a pH of no more than 12 and operates to release the nucleic acid material from the polymer under relatively low temperature conditions, typically no more than 50° C., and in particular instances, no more than 40° C. The glycol material may comprise a monomeric glycol such as ethylene glycol, propylene glycol, or the like, or it may comprise a polymeric glycol such as polyethylene glycol. Also disclosed is a novel positively charged polymer which may be employed in the separation process. This polymer comprises an acidified polyamine, such as polyethyleneimine which has been reacted with a nonacidified polyethyleneimine in a coupling reaction.

Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.

Abstract: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Abstract: The present invention deals with a novel aromatic di-isoimide chemical compound that has utility as a catalyst and as a curing agent in epoxy compositions. The di-isoimide serves effectively as a thermally activated latent catalyst in epoxy curing, thereby increasing shelf life, and avoids premature cross-linking. Novel laminated articles and printed wiring boards, including encapsulated printed wiring boards are also disclosed. The composition hereof also can be used as a flame retardant in thermoplastic and thermoset polymers.

Abstract: This invention relates to flexible cycloaliphatic diisocyanate trimers and a process for the preparation of these. These flexible products are allophanate-modified, partially trimerized cycloaliphatic diisocyanates and are characterized by a low Tg. More specifically, the Tg of the resultant product ranges from about ?30° C. to about 40° C., after the excess monomer has been removed from the product.

Abstract: The present invention relates to water-soluble photochromic compounds for labeling biomolecules and a method of detecting biomolecules using the same. More specifically, relates to water-soluble photochromic compounds for labeling biomolecules, in which a functional group rendering photochromic molecules water-soluble is linked to a functional group capable of binding to biomolecules, and a method of detecting biomolecules using the same. Because the disclosed water-soluble photochromic compounds exhibit the color corresponding to the wavelength of visible light range, they allow signals to be easily detected not only with an UV-VIS spectrophotometer but also visually. Accordingly, the photochromic compounds can be advantageously used in sensors for diagnosing diseases.

Abstract: A class of luminescent gold(III) compounds containing a tridentate ligand with one strong ?-donating group having the chemical structure depicted by generic formula (I): wherein: (a) X is selected from nitrogen; (b) Y and Z selected from carbon; (c) A is cyclic structure derivative of pyridine group; (d) B and C are cyclic structure derivative of phenyl groups; (e) R1 is an optionally substituted carbon donor ligand attached to the gold atom; (f) n is zero, a positive integer or a negative integer.

Abstract: The present invention provides an efficient process for the preparation of hexahydroisoquinolines from dihydroisoquinolines. In particular, the invention provides a good yielding, one-pot process for the synthesis of hexahydroisoquinolines.

Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.

Abstract: An intermediate of formula (II)

Abstract: The present invention provides dye compounds optimally excited at about 400 nm and have a Stokes shift of at least about 80 nm. These dyes find use in detection of analyte in a sample and the preparation of dye-conjugates.

Abstract: The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.

Abstract: The present invention relates to a novel compound having plasminogen activator inhibitor-1 (PAI-1) inhibitory activity, and a PAI-1 inhibitor comprising the compound as an active ingredient. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. The novel compound is represented by the following general formula. Each symbol is defined as those in the specification.

Abstract: The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.

Abstract: New forms of Febuxostat have been prepared and characterized. These forms are useful, for example, in the chronic management of hyperuricemia in patients with gout.

Abstract: Compounds useful for treating hepatitis C virus infection. The compounds are of formula (I): wherein A, B, C, D, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, m, n, p, q, r, t, u, and v are defined herein. Also disclosed is a method for treating hepatitis C virus infection with these compounds.

Abstract: The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Abstract: The present invention relates to certain substituted tricyclic acid derivatives of Formula (I) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.

Abstract: Methods for preparation of isoindolin-1-one compounds are described.

Abstract: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.

Abstract: The present invention is a process for preparing (3R)-2?-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4?(1?H)-pyrrolo[1,2-a]pyrazine]-1?,2,3?,5(2H?)-tetraone, comprising, for example, the following steps: (1) reacting a compound of the formula (III) wherein R is a C1-6 alkyl group, with 2,5-dimethoxytetrahydrofuran to provide a compound of the formula (IV) wherein R is a C1-6 alkyl group; (2) reacting the compound of the formula (IV) wherein R is a C1-6 alkyl group, with trichloroacetyl chloride to provide a compound of the formula wherein R is a C1-6 group; and (3) reacting the compound provided in step (2) with 4-bromo-2-fluorobenzylamine to provide (3R)-2?-(4-bromo-2-fluorobenzyl)spiro-[pyrrolidine-3,4?(1?H)-pyrrolo[1,2-a]pyrazine]-1?,2,3?,5(2H?)-tetraone.

Abstract: Compounds of the formula I, in the form of mixtures comprising predominantly one enantiomer or in the form of pure enantiomers, secondary phosphine-Q-P*(?O)HR1 (I) in which secondary phosphine is a C-bonded, secondary phosphine group —P(R)2; in which R is in each case independently hydrocarbon radicals or heterohydrocarbon radicals; Q is a bivalent, achiral, aromatic base skeleton, a bivalent, achiral ferrocene base skeleton, an optionally substituted bivalent cycloalkane or heterocycloalkane skeleton, or a C1-C4-alkylene skeleton, and in which base skeletons a secondary phosphine group is bonded directly to a carbon atom, or, in the case of cyclic base skeletons, directly to a carbon atom or via a C1-C4-alkylene group, and in which base skeletons a P-chiral group —P*(O)HR1 is bonded to a carbon atom such that the phosphorus atoms are linked via 1 to 7 atoms of a carbon chain optionally interrupted by heteroatoms from the group of O, S, N, Fe or Si; P* is a chiral phosphorus atom; and R1 is a hydrocarbon radi

Abstract: The invention provides compounds that are A-type procyanidins. The compounds can be prepared by reacting flavylium salts with catechins or analogs thereof, for example, under anhydrous conditions in alcohol.

Abstract: A novel epoxy compound represented by the following formula and a method for producing the same are provided: wherein R1 and R2 are members selected from the group consisting of hydrogen, aliphatic hydrocarbon group having 1 to 4 carbon atoms, alicyclic hydrocarbon group having 3 to 6 carbon atoms, aromatic hydrocarbon group having 6 to 10 carbon atoms, halogen atom, ether group, ester group, acyl group and nitro group, n is an integer of 1 to 4, and m is an integer of 1 to 5.

Abstract: The present invention is directed to a method of exchanging nanostructures from within aqueous liquid media into organic liquid media. The steps comprise first supplying solid nanostructures in an aqueous liquid media, adjusting the pH, incorporating an ionic surfactant sufficient to reduce nanostructure aggregation, followed by concentrating the nanostructures in the aqueous liquid media. The nanostructures may them be placed in organic liquid media followed by introduction of a coupling agent capable of covalent attachment to the nanostructure surface while providing a functional group capable of polymerization to covalently bond the nanostructures to a selected monomer and/or polymer resin.

Abstract: Certain metallocene compounds are provided that, when used as a component in a supported polymerization catalyst under industrially relevant polymerization conditions, afford high molar mass homo polymers or copolymers like polypropylene or propylene/ethylene copolymers without the need for any ?-branched substituent in either of the two available 2-positions of the indenyl ligands. The substituent in the 2-position of one indenyl ligand can be any radical comprising hydrogen, methyl, or any other C2-C40 hydrocarbon which is not branched in the ?-position, and substituent in the 2-position of the other indenyl ligand can be any C5-C40 hydrocarbon radical with the proviso that this hydrocarbon radical is branched in the ?-position and that the ?-carbon atom is a quarternary carbon atom and part of a non-cyclic hydrocarbon system. This metallocene topology affords high melting point, very high molar mass homo polypropylene and very high molar mass propylene-based copolymers.

Abstract: The subject invention pertains to metal organic frameworks (MOF) having zeolite-net-like topology, their methods of use, and their modes of synthesis. The ZMOFs are produced by combining predesigned tetrahedral building, generated in situ using heterochelation, with polyfunctional ligands that have the commensurate angle and the required donor groups for the chelation. Each molecular building block is contrasted of a single metal ion and ligands with both heterochelation functionality and bridging functionality. Advantageously, zeolite-net-like MOFs of the subject invention are porous and contain large functional cavities, which is useful for encapsulating large molecules.

Abstract: The present invention relates to novel 1,4-disilacyclohexane derivatives and a preparation method thereof. More particularly, the present invention provides a method for preparing 1,4-disilacyclohexane derivatives with a hexagonal ring structure at high yield through double silylation of an organosilane compound and a vinyl silane compound having an unsaturated double bond using quarternary organophosphonium salts as a catalyst. According to the present invention, tris(silyl)ethanes having three silyl groups in one molecule can be prepared at the same time and the catalyst can be recovered after reaction. Thus, the method is economical and enables mass-production of 1,4-disilacydohexane derivatives and tris(silyl)ethanes which are precursors of organic/inorganic hybrid materials.

Abstract: Processes for the alcoholysis, inclusive of transesterification and/or disproportionation, of reactants are disclosed. The alcoholysis process may include feeding reactants and a trace amount of soluble organometallic compound to a reactor comprising a solid alcoholysis catalyst, wherein the soluble organometallic compound and the solid alcoholysis catalyst each independently comprise a Group II to Group VI element, which may be the same element in various embodiments. As an example, diphenyl carbonate may be continuously produced by performing transesterification over a solid catalyst followed by disproportionation, where a trace amount of soluble organometallic compound is fed to the transesterification reactor.

Abstract: The present invention relates to polyesters prepared from benzene, cyclohexene and cyclohexane compounds having carboxylic acid groups at the 1 and 4, and optionally the 2, positions, such as terephthalic acid or dimethyl terephthalates, and alkylene glycols, such ethylene glycol or 1,4-butane diol. The invention also relates to processes for preparing such polyesters. The invention also relates to such polyesters derived from starting materials derived from renewable resources.

Abstract: The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds.

Abstract: In industrial scale production of acrolen and/or acrylic acid by catalytic gas-phase oxidation of propylene or a propylene-containing gas with molecular oxygen or a molecular oxygen-containing gas or in industrial scale production of acrylic acid by catalytic gas-phase oxidation of acrolein or an acrolein-containing gas with molecular oxygen or a molecular oxygen-containing gas, this invention provides a process characterized in that the initial stage operation is carried out under advancedly elevated reaction temperature and thereafter the reaction temperature is lowered to carry out the steady state operation. According to this process, acrolein and/or acrylic acid can be produced in high yield stably over prolonged period.

Abstract: Dyes for a dye-sensitized solar cell are provided. The dyes for a dye-sensitized solar cell have a structure of wherein each of X and Y independently comprises a substituent, comprising a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted aromatic heterocyclic group, and combinations thereof, and at least one of the X and Y comprises an aromatic group which are substituted a pyrene derivative substituted with an alkyl group or an aryl group, and Z comprises a substituted or unsubstituted aromatic hydrocarbon group, a substituted or unsubstituted heterocyclic group, a vinyl group, and a substituted or unsubstituted polyvinyl group, and A comprises an acid functional group.

Abstract: A process for preparing amines of the formula I, by reacting a carbonyl compound of the formula II with an amine of the formula III where R1 and R2 are different and are each an organic radical which has from 1 to 20 carbon atoms and may optionally also comprise heteroatoms, R3 is a C1-C6-alkyl group and R4 is an aryl group which may be partly or fully halogenated and/or may bear from one to three radicals from the group of cyano, nitro, C1-C6-alkyl, C1-C6-haloalkyl, hydroxyl, C1-C6-hydroxyalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, hydroxycarbonyl, C1-C6-alkoxycarbonyl, C1-C6-alkylamino, di(C1-C6-alkyl)amino, aryl and aryl(C1-C6-alkyl); and * represents the S or R configuration, and ** represents the S and/or R configuration; which comprises performing the reaction in the presence of a heterogeneous imination catalyst, of a hydrogenation catalyst and of hydrogen.

Abstract: The present invention is directed to methods and compositions for making and using a new polymorph of cinacalcet hydrochloride.

Abstract: A reaction column (12) to which a raw material mixture (11) containing a mono-lower-alkylamine (AA: raw material I) and an alkylene oxide (AO: raw material II) is supplied, an unreacted raw material distillation column (14) that separates an unreacted raw material (15) from a reaction product (13a) (containing the unreacted raw material (15), a target reaction product (monomer) (17), and a by-product (dimer) (18)), and a flash drum (16) to which a reaction product (13b) (containing the target reaction product (monomer) (17) and the by-product (dimer) (18)) is supplied, the flash drum (16) separating a mono-lower-alkyl monoalkanolamine (monomer, the target reaction product 17) in a gas state, are provided.

Abstract: Disclosed is a method for preparation of 1,1-diamino-2,2-dinitroethylene (DADNE) through the hydrolysis of 4,6-dihydroxy-5,5-dinitro-2-(dinitromethylene)-2,5-dihydropyrimidine (DHDNDP) obtained by the nitration of 4,6-dihydroxy-2-methylpyrimidine (DHMP), which can avoid eruption or sudden frothing of a reaction solution on a lab scale and even a large scale preparation as well as reduce the reaction time.

Abstract: The disclosure provides a catalyst carrier, including a nano carbon material; and a polymer grafted on the nano carbon material, wherein the polymer has a repetitive unit comprising a phosphorous atom. The disclosure further provides a catalyst deposited on the catalyst carrier of the disclosure. The catalyst of the disclosure has high reactivity, and is easy to be recovered in C—C coupling reactions such as a Suzuki-Miyaura coupling reaction.

Abstract: The invention relates to 2-methylene-5-substituted-methylenecyclopentanone derivatives of formula I, and the use thereof. The derivatives of formula I as active components are useful for preparing a medicine for the treatment and/or prevention of cancer diseases such as breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, uterus cancer, pancreatic cancer and ovary cancer. The active compounds of the invention may be used as an anticancer drug alone or used in combination with one or more other antitumor drugs. A combined therapy can be carried out by administrating each therapeutic component concurrently, subsequently or separately.

Abstract: The present invention provides energy and economically efficient and environmentally responsible processes for using acetone to dry, dehydrate and/or dewater various hydrated feedstocks.

Abstract: Cocrystals of pterostilbene are disclosed, including: pterostilbene:caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene:glutaric acid cocrystal, and pterostilbene:piperazine cocrystal. The pterostilbene:caffeine cocrystal is polymorphic. Forms I and II of the pterostilbene:caffeine cocrystal are disclosed. The therapeutic uses of the pterostilbene cocrystals and of pharmaceutical/nutraceutical compositions containing them are also disclosed. The disclosure sets out various methods of making and characterizing the pterostilbene cocrystals.

Abstract: A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate.